162 results about "Poor prognosis" patented technology

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.

The invention provides an in vitro method for determining the prognosis of a patient with stroke comprising: (i) determining, in a sample isolated from the patient, the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof, (ii) comparing the level of expression obtained in step (i) with a corresponding reference value, wherein if the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a bad prognosis. The invention also provides an in vitro method for deciding or recommending whether to initiate a medical regimen in a patient with stroke, and an in vitro method for determining the response of a patient already diagnosed with stroke, to a medical regimen for treating stroke. The invention further provides a miRNA inhibitor of a miRNA selected from the list consisting of miR-376c- 3p, miR-199a and combinations thereof, for use in the treatment or prevention of stroke in a patient. The invention also provides a combination of miRNAs comprising said miRNA inhibitor, and a pharmaceutical composition for use in the treatment or prevention of stroke.

The invention belongs to the field of tumor medicine and the technical field of molecular biology and gene detection, and relates to application of rs17771861 in preparation of a nasopharyngeal carcinoma prognosis prediction marker, and the sequence of the SNP site rs17771861 is as shown in SEQ ID NO.1. The invention also relates to application of the SNP site rs17771861 in preparation of a nasopharyngeal carcinoma prognosis prediction marker. The invention provides an SNP (Single Nucleotide Polymorphism) marker rs17771861 related to nasopharyngeal carcinoma prognosis, application of the SNP marker rs17771861 and a detection kit capable of being used for nasopharyngeal carcinoma prognosis prediction, and the SNP marker rs17771861 is used for assisting in guiding individualized treatment and improving prognosis of tumor patients. After the kit disclosed by the invention is applied to clinical detection, prognosis of a patient can be evaluated before treatment, and a more positive and effective treatment scheme is formulated for the patient with poor prognosis, so that individualized treatment of the patient is realized, and the survival rate is increased. In addition, the kit only needs to detect peripheral blood, and has the characteristics of convenience in sampling, simplicity in operation, high timeliness and the like.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of GJB6 in preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent and screening of drugs for targeted treatment of esophageal squamous cell carcinoma. The low expression of the GJB6 is applied to preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent. GJB6 is low in expression in ESCC patients, and ESCC prognosis is poor. And the prognosis of patients with high expression of GJB6 is better. Overexpression of GJB6 inhibits ESCC cell proliferation, migration and invasion and in-vivo tumor enlargement. The GJB6 plays a role of a cancer suppressor gene in ESCC and inhibits cell proliferation, migration and invasion. The AKT signal channel is one of downstream channels for GJB6 to regulate the occurrence and development of ESCC. The AKT inhibitor effectively inhibits GJB6 low-expression ESCC malignant phenotypes, including enhancement of cell proliferation and migration invasion ability and in-vivo tumor enlargement. The AKT is a key therapeutic target of the GJB6 low expression type ESCC.

Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.

The present invention relates to the treatment of cancer, including colorectal cancer (CRC), by inhibiting or blocking Annexin 1. The present invention also relates to the prevention of CRC in high risk patients by inhibiting or blocking Annexin A1. The present invention also relates to the reduction of chemotherapy resistance by inhibiting or blocking Annexin A1. The present invention also relates to the detection of poor prognosis in subjects with CRC by detecting or measuring the expression level of ANXA1 and / or the protein level of Annexin 1.

The invention belongs to the technical field of gene engineering, and particularly relates to application of an SSRP1 and / or SUPT16H gene inhibitor in treatment of hepatocellular carcinoma. The invention provides an application of an inhibitor of SSRP1 and / or SUPT16H genes in preparation of a pharmaceutical composition for treating cancers. According to the invention, the high expression of SSRP1 and SUPT16H is obviously related to poor prognosis through pan-cancer analysis of SSRP1 and SUPT16H. In liver cancer, the FACT is preferentially enriched in liver cells, and the expression of the FACT is increased along with the increase of quasi time, which indicates that the FACT participates in tumor evolution and transcriptome reprogramming processes. According to the invention, FK866 and NPK76-II-72-1 are screened as potential inhibitors through drug sensitivity analysis, and FK866 and NPK76-II-72-1 are screened as the potential inhibitors. Therefore, an inhibitor of the SSRP1 and / or SUPT16H gene can be used for prognosis evaluation of the hepatocellular carcinoma patient, and can be used as a treatment target of the hepatocellular carcinoma patient.

The invention provides a biomarker for predicting chemosensitivity of acute myelogenous leukemia and application of the biomarker, and belongs to the technical field of biological medicine. The leptin and fumaric acid provided by the invention can be used as biomarkers for predicting AML chemotherapy resistance. Wherein the leptin influences the chemotherapy sensitivity by regulating metabolic pathways such as mitochondrial OXPHOS and mitochondrial active oxygen mtROS; meanwhile, the invention also discloses a new mechanism that fumaric acid promotes BMSCs to transfer mitochondria to AML cells so as to enhance the OXPHOS level and induce Ara-C drug resistance. The levels of the two are obviously related to the chemotherapy reaction and prognosis stratification of the patient, so that early recognition of the patient with chemotherapy resistance or poor prognosis is facilitated. Leptin and fumaric acid can be detected in bone marrow plasma, the feasibility is high, and clinical transformation is facilitated. By detecting the level of leptin or fumaric acid in bone marrow of a patient, individualized treatment can be achieved, and the survival rate of the patient is increased.

The invention relates to the technical field of skin ulcers, and discloses a skin ulcer prognosis prediction method and system based on a column diagram, and the method comprises the steps: obtaining a clinical feature data set of a patient; preprocessing the clinical feature data set to obtain a preprocessed clinical feature data set; inputting the preprocessed clinical feature data set into a pre-trained ulcer prognosis prediction model to obtain weight coefficients of independent risk factors; constructing a visual scoring system according to the weight coefficient; and according to a scoring result in the visual scoring system, predicting an ulcer prognosis poor probability. According to the skin ulcer prognosis prediction method and system based on the column diagram, the independent risk factors influencing ulcer prognosis are explored, and the prediction model is established through the regression curve and the column diagram, so that a patient with poor ulcer prognosis is identified, a more reasonable treatment scheme is established in the early stage of a disease, and the healing time of the ulcer is shortened.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The present invention discloses the application of CIR1 as a molecular marker in the diagnosis, treatment and prognosis evaluation of lung cancer bone metastasis, and belongs to the field of medical tumor diagnosis and treatment. The present invention found that CIR1 is highly expressed in tissues and cells of lung cancer bone metastasis, and is accompanied by a poor prognosis. In vivo and in vitro experiments confirmed that CIR1 downregulation can significantly inhibit the proliferation and migration ability of lung cancer cells, thereby inhibiting bone metastasis; at the same time, CIR1 downregulation can significantly inhibit the differentiation and maturation of lung cancer cells on osteoclasts, greatly reducing the occurrence of osteolytic destruction. Therefore, the present invention proposes to use a reagent for detecting the expression level of CIR1 in the preparation of a kit for detecting whether lung cancer has bone metastasis and / or a prognostic kit for predicting the tendency of lung cancer bone metastasis; and to use a CIR1 inhibitor in the preparation of a drug for preventing, alleviating and / or treating lung cancer bone metastasis, providing a new idea for the diagnosis, prognosis and treatment of lung cancer bone metastasis.

The present invention discloses a method and system for mining potential proto-oncogenes based on the three-dimensional structure of chromatin, which relates to the field of computational biology technology. The method comprises: obtaining multiple mutation insulation regions based on chromatin data and cancer mutation data, and inputting the regions into a trained binding site predictor to obtain prediction results and destroyed insulation regions; obtaining multiple differentially expressed gene sets based on cancer gene expression data, intersecting the multiple differentially expressed gene sets to obtain a final differentially expressed gene set; intersecting the final differentially expressed gene set and the genes in the destroyed insulation regions to obtain intersection genes; performing survival analysis to obtain analysis results, screening the intersection genes based on the analysis results to obtain genes associated with poor prognosis; and screening the intersection genes to obtain potential proto-oncogenes. This improves the accuracy and reliability of mining potential proto-oncogenes while saving time and economic expenses.

The invention belongs to the technical field of biological medicine, and particularly relates to application of GLUT5 serving as a colorectal cancer biomarker in development of an in-vitro detection kit, a prognosis model and an inhibitor. The GLUT5 is highly expressed in colorectal cancer tumor-related fibroblasts (CAFs), the expression level of the GLUT5 is remarkably related to poor prognosis of a patient, and the GLUT5 can be used as a molecular basis for auxiliary diagnosis and an independent prognosis factor. In mechanism, the GLUT5 promotes tumor progression by mediating fructose metabolism reprogramming of the CAFs. A full-chain solution from early diagnosis and precise prognosis to targeted therapy is provided for colorectal cancer, and the clinical transformation value is remarkable.

The present invention relates to the field of medical data processing technology, and specifically to an integrated medical-nursing-patient follow-up support system for preventing complications after TIPS surgery. The system comprises a data acquisition module, a complication risk expression degree acquisition module, and a risk warning module. The system is used to obtain the patient's normal blood ammonia level, heart rate, systolic blood pressure dispersion increase, average protein intake, and the postoperative stage to which they belong, obtain the patient's physical recovery degree at each follow-up time, and obtain a recovery state time series; obtain the patient's poor prognosis level, compensate for the poor prognosis level to obtain the patient's recovery risk coefficient; obtain the patient's physical sign risk coefficient, obtain the patient's complication risk expression degree, and provide an early warning of postoperative complication risks. The present invention aims to avoid the influence of the patient's recovery status and physical sign data when analyzing TIPS postoperative complications, thereby improving the accuracy of analyzing TIPS postoperative complications.

The invention discloses an application of HILAR in preparation of a product for predicting non-small cell lung cancer prognosis and lung adenocarcinoma metastasis risk, and particularly provides an application of a reagent for detecting the expression level of HILAR in preparation of a related kit, and a detection method comprises qPCR or RNA-FISH. Clinical sample analysis shows that the expression of the HILAR in non-small cell lung cancer patients with metastasis is obviously higher than that of non-metastasis patients, and the high expression of the HILAR is closely related to poor prognosis of the patients; in-vitro function experiments prove that overexpression of HILAR can significantly enhance the migration and invasion ability of lung adenocarcinoma cells; an in-vivo animal model shows that overexpression of the HILAR can obviously promote the metastasis and colonization capability of lung adenocarcinoma cells in a mouse body. Results show that the HILAR can be used as an important biomarker for predicting non-small cell lung cancer metastasis and evaluating prognosis, and a solid experimental basis and application prospect are provided for developing related diagnostic kits.

The invention discloses a kit for predicting the treatment effect of a combined drug composition for cervical cancer, which predicts the treatment effect of a'VEGFR inhibitor + PD-1 monoclonal antibody 'combined scheme by detecting serum arginine or SLC6A14 expression quantity in cervical cancer tissues, can help patients to select the treatment scheme in a more targeted manner, can improve the effectiveness of drug use, and has the advantages of simple operation, low cost and high efficiency. And poor prognosis or treatment opportunity delay caused by selection of treatment schemes is avoided, and the method has a good application prospect.

The invention belongs to the technical field of biological medicine, and particularly discloses application of CCL28 as a biomarker and a therapeutic target in sepsis. The invention particularly relates to application of a CCL28 gene or a detection reagent for the expression quantity of the CCL28 gene in preparation of a kit for diagnosis or prognosis monitoring of sepsis. The expression of the novel immunomodulatory factor CCL28 in a sepsis patient is obviously improved, and the expression level of the novel immunomodulatory factor CCL28 is in obvious negative correlation with poor prognosis of sepsis. Through CLP induction of a sepsis mouse model, the invention finds that the expression level of CCL28 in sepsis mouse blood, abdominal cavity lavage fluid (PLF), liver and kidney is significantly increased. By adopting the recombinant CCL28 for treatment, the bacterial load in the mice with sepsis can be remarkably reduced, and the multi-organ injury of the mice with sepsis can be reduced, so that the survival rate of the mice with sepsis can be remarkably improved. In conclusion, the invention explores a novel immunomodulatory protein CCL28, and the novel immunomodulatory protein CCL28 not only can be used as a diagnosis and prognosis biomarker of sepsis, but also can be used as a novel target spot for treating sepsis.

The invention discloses application of MC1R, particularly relates to application of a reagent for inhibiting MC1R in preparation of a medicine for treating colorectal cancer, and belongs to the field of biological medicine. In-vitro experiments show that over-expression of the MC1R in a colorectal cancer cell line can promote cell proliferation and migration, meanwhile, ferroptosis is inhibited by down-regulating ACSL4 expression, and the reverse effect is generated by knocking down the MC1R. In-vivo experiments also find that both the volume and the weight of a xenotransplantation tumor formed by colorectal cancer cells knocking down the MC1R are reduced, and the MC1R activates a Notch signal channel to cause expression inhibition of ACSL4, so that ferroptosis is inhibited, and cell growth and migration are further blocked; the high expression of MC1R in colorectal cancer is related to poor prognosis and is negatively related to ferroptosis level. Targeting MC1R may provide a new strategy for enhancing colorectal cancer ferroptosis, and provides an important clue for developing colorectal cancer targeted therapy.

The application discloses application of CPSF7 as an ovarian cancer treatment and prognosis target, and relates to the technical field of biological medicine.The application research finds that overexpression of CPSF7 is related to poor prognosis of ovarian cancer, indicating that CPSF7 can be used as a prognosis index and potential treatment target of ovarian cancer.Further research shows that CPSF7 promotes malignant progression of ovarian cancer by promoting proliferation, migration and invasion of ovarian cancer cells, and inhibition of CPSF7 expression can significantly inhibit proliferation, migration and invasion of ovarian cancer cells.The application also finds that UBE2K is one of key downstream targets of CPSF7 in the ovarian cancer cell-mediated carcinogenic process, and inhibition of UBE2K expression can weaken the overexpression of CPSF7 induced enhancement effect of ovarian cancer cell proliferation, migration and invasion.The application provides a new target for treatment and prognosis prediction of ovarian cancer, and has important clinical application value.

The invention relates to application of a SelK gene or an expression product thereof as a biomarker for prognosis judgment of glioblastoma diseases. The invention discloses application of a SelK gene or an expression product of the SelK gene to preparation of a product for performing glioblastoma typing diagnosis, therapeutic schedule selection and / or prognosis evaluation by detecting the level of the SelK gene or the expression product of the SelK gene in a tumor sample obtained from an object. The research shows that the high-expression SelK gene and the protein expression product thereof are both in negative correlation with poor prognosis of glioblastoma, and survival analysis also proves that the overall prognosis of patients with low SelK expression is obviously superior to that of patients with high SelK expression, so that the SelK gene and the expression product thereof can be used as molecular markers for prognosis evaluation and treatment effect. The invention also provides an application of the targeted SKP2 / beta-TrCP1 / CDK4 axis signal channel in preparation, evaluation or screening of drugs for treating glioblastoma.

The invention provides a state prediction method and device for a traumatic patient, electronic equipment and a storage medium, and belongs to the technical field of artificial intelligence. The method comprises the following steps: acquiring state parameters of a traumatic patient, wherein the state parameters comprise multiple of gender, age, systolic pressure, diastolic pressure, noninvasive blood pressure average value, heart rate, respiratory rate and oxyhemoglobin saturation; standardizing the state parameters to obtain input parameters; inputting the input parameters into a prediction model to obtain a first prediction probability output by the prediction model; wherein the first prediction probability is the probability that the traumatic patient has hemorrhagic shock, the probability that the traumatic patient needs to be infused with erythrocyte products of more than a set unit, the probability that the traumatic patient needs to receive an operation within a set time or the probability that the traumatic patient has poor prognosis. According to the invention, the shock probability, the probability of infusing red blood cell products, the probability of needing operations or the probability of poor prognosis of the traumatic patient can be predicted according to the state parameters of the traumatic patient.

The present invention discloses the application of a novel molecular marker in the diagnosis or prognosis assessment of breast cancer. Specifically disclosed are the application of the molecular marker lncRNA LIVAR and / or a substance for detecting the molecular marker in the diagnosis, auxiliary diagnosis, screening, prognosis assessment, and risk assessment of breast cancer, as well as its application as a target in the prevention or treatment of breast cancer. The expression level of LIVAR in breast cancer patients is significantly upregulated, and the high expression of LIVAR is significantly correlated with a poor prognosis of breast cancer (including triple-negative breast cancer). Experiments have shown that inhibiting the expression of LIVAR can significantly inhibit the migration and / or invasion ability of breast cancer cells, and can significantly inhibit the proliferation of breast cancer cells. It shows that it can be used as a target for the treatment of breast cancer, the substance that inhibits the expression of LIVAR can be used to prepare a drug for treating breast cancer, and the substance that detects LIVAR can be used for the diagnosis or prognosis of breast cancer.

This disclosure presents methods and reagents for cancer prognosis and treatment based on APOE genotyping. Specifically, the presence of the APOE2 genotype is indicative of a poor prognosis for the subject, whereas the presence of the APOE4 genotype is indicative of a good prognosis for the subject. The disclosed methods and reagents are useful for treating cancer and for making medical and clinical decisions on adjuvant therapy, tumor surveillance, and the likelihood of disease progression.

The invention relates to a biomarker combination for treating SHH subtype medulloblastoma, and aims to solve the problems that existing treatment targets are deficient, the curative effect is limited and precise treatment is insufficient. The invention reveals that an m6A-YTHDF2 signal axis is a novel treatment target of SHH-MB for the first time, the YTHDF2 regulates and controls the expression of a downstream target gene DENND2A through an m6A dependency mode, the high expression of the YTHDF2 is related to poor prognosis of a patient, and knock-down of the YTHDF2 can significantly inhibit the proliferation and balling ability of SHH-MB cells. According to the invention, the TET-ON regulated SHH-MB cell line capable of inducing to knock down YTHDF2 is constructed, and a tool is provided for drug screening; it is clear that a YTHDF2 inhibitor (such as DC-Y13-27 and the like) can achieve the anti-tumor effect by down-regulating DENND2A expression, and the drug sensitivity of SHH-MB tumor cells to a Hedgehog signal channel small molecule inhibitor Vismodegib (GDC-0449) is improved.

The invention discloses a pancreatic cancer diagnosis marker and application thereof, and belongs to the technical field of biological medicines, a serological marker for pancreatic cancer diagnosis is thymosin beta-10, namely Tbeta10, a biomarker for pancreatic cancer diagnosis is a gene TMSB10 for coding the Tbeta10, the gene is 9168 in an NCBI database, a qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, a qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2, the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.1, the qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, and the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2. Tbeta10 protein or TMSB10 gene high expression serves as a biomarker for diagnosis and poor prognosis of a pancreatic cancer patient, it is determined that the content of Tbeta10 in serum of the pancreatic cancer patient is remarkably increased, the Tbeta10 protein or TMSB10 gene high expression serves as a serum marker for diagnosis and curative effect and prognosis monitoring of the pancreatic cancer, and the total survival rate of the pancreatic cancer patient is reduced; the TMSB10 is used as a biomarker for poor prognosis of pancreatic cancer patients.

The present invention includes methods for treating a FLT3 mutated proliferative disorder comprising: measuring expression of a mutated FLT3 and a one or more driver mutations in a nuclear transport protein that results in a loss of localization of the nuclear transport protein in a sample obtained from a tumor sample obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof, wherein the Crenolanib increases a chance of survival of the patient having both the mutated FLT3 and mutation in NPM1 or NUP98, wherein the Crenolanib, as shown below, is administered to a subject suffering from said disorder:

The invention discloses construction and application of a poor heart failure prognosis risk prediction model. Specifically, the invention provides a construction method of a poor heart failure prognosis risk prediction model, which comprises the following steps: (s1) providing a first data set which comprises poor heart failure prognosis risk marker data, the biomarker comprises the following metabolites from intestinal flora: trimethylamine oxide (TMAO), acetyl L-carnitine (ALC), choline chloride (CC), gamma-butyl betaine (gamma-BB) and L-carnitine (LC); and (s2) constructing a risk prediction model of acute attack or deterioration of the heart failure patient according to the risk marker data. The risk prediction model has excellent prediction capability of poor prognosis of heart failure.

The invention provides a risk prediction system and application of EB virus related hemophagocytic syndrome patients, five indexes UREA, DB, hscTnI, Ferr and PT are researched and developed to construct a scoring system, and if the score is greater than or equal to 3, the patient is prompted that the 28-day prognosis adverse risk is obviously increased (OR = 1.915). The model can provide a dynamic risk assessment tool for clinic and guide individualized treatment decisions.

The present application belongs to the technical field of biomarkers, and particularly relates to a breast cancer biomarker and application thereof. The present application first identifies long-chain non-coding RNA CCLA, and confirms that the expression of CCLA in triple-negative breast cancer tissue is significantly higher than that in normal tissue, and high expression is closely related to poor prognosis of patients. Through RT-qPCR verification and survival analysis of 81 TNBC clinical samples, the potential of CCLA as a specific biomarker of TNBC is confirmed, a new specific target for precise diagnosis and treatment of TNBC is provided, and the shortage of TNBC target points in the prior art is effectively overcome.

The application discloses application of SMOX in preparation of a colorectal cancer diagnosis or prognosis prediction product, and relates to the field of biotechnology.It is proved that the expression of SMOX in colon cancer and rectal cancer tissues is higher than that in normal tissues, and high expression of SMOX is related to poor prognosis of colon cancer.The application applies SMOX to diagnosis or prognosis prediction of colorectal cancer, thereby providing a new source for preparation of a colorectal cancer diagnosis or prognosis prediction product, and discovering new medical value of SMOX.